 HIV
and AIDS Articles |
Therapies
for Treatment-Experienced Patients |
| Genotypic
Testing Predicts Response to Maraviroc (Selzentry)
as well as Viral Tropism Testing |
| Once-daily
Lopinavir/ritonavir (Kaletra) Works as Well
as Twice-daily dosing in Treatment-naive HIV Patients |
| Once
Daily Darunavir/ritonavir: Experience in a
Single Centre |
| FOTO
Study Finds 5 Days On, 2 Days Off Treatment Strategy Maintains HIV
Suppression while Reducing Cost |
 |
| First-Line
Therapy for Treatment-Naive Patients |
| Treatment-naive
Patients with Confirmed CCR5-tropic HIV Continue to Respond Well to Maraviroc
(Selzentry) at 96 Weeks in the MERIT Study |
| Nevirapine
(Viramune) Has Equal Efficacy but a More Favorable Lipid Profile Compared
with Boosted Atazanavir (Reyataz) |
| Once
Daily Darunavir/ritonavir: Experience in a
Single Centre |
| | Integrase
Inhibitor Raltegravir (Isentress) Compares
Favorably to Efavirenz (Sustiva) at 144 Weeks
in Treatment-naive Patients |
|
| Experimental
HIV Therapies |
| Potent
Next-generation Experimental Integrase Inhibitor S/GSK134957
Debuts at IAS 2009 |
|
| Adverse
Events |
| Lipid
and Glucose Changes Related
to Boosted Darunavir (Prezista) in Children and Adolescents with HIV: DELPHI Study |
| HIV
Positive People without Viral Hepatitis or Other Risk
Factors Have a Fibrosis Distribution Similar to the General Population |
| Liver
Toxicity Related to Raltegravir (Isentress) Is Uncommon among HIV Patients,
including those with HIV-HCV Coinfection |
| Impact
of Adverse Events on Survival of African HIV
Patients in the DART Trial |
| Confounding
Factors May Explain Elevated Cardiovascular Risk
in Patients Taking Abacavir |
| Intensive
Cardiovascular Intervention Lowers Blood
Lipids in HIV Patients on Antiretroviral Therapy |
|
| HIV
Transmission and Prevention |
| Daily
Acyclovir (Zovirax) Delays HIV Disease Progression
in People Coinfected with HIV and Herpes Simplex Virus Type 2 |
|
| Related
Conditions |
| Presence
of Human Papillomavirus (HPV) Increases Risk
of HIV Infection |
| HIV
Positive People without Viral Hepatitis or Other Risk
Factors Have a Fibrosis Distribution Similar to the General Population |
| Daily
Acyclovir (Zovirax) Delays HIV Disease Progression in People Coinfected with HIV
and Herpes Simplex Virus Type 2 |
| Longer
Duration of HIV Infection and Detectable Viral Load Linked to Higher Risk of Non-AIDS-defining
Cancers |
| Intensive
Cardiovascular Intervention Lowers Blood
Lipids in HIV Patients on Antiretroviral Therapy |
| IAS
2009 Opening Session Emphasizes Need for Expanded Treatment of HIV
and Tuberculosis in Developing Countries |
| Research
Offers Guidance on Scaling Up HIV and Tuberculosis Treatment
Programs in Resource-limited Countries |
| Widespread
Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis
Prevalence in South Africa |
| HIV
Latency Is a Myth: New HIV Paradigm May Focus on Inflammation |
|
| Developing
Countries |
| Can
People in Low-income Countries Benefit from
Antiretroviral Therapy without Routine Laboratory
Monitoring? |
| Impact
of Adverse Events on Survival of African HIV Patients
in the DART Trial |
| IAS
2009 Opening Session Emphasizes Need for Expanded Treatment of HIV and Tuberculosis
in Developing Countries |
| Research
Offers Guidance on Scaling Up HIV and Tuberculosis Treatment Programs in Resource-limited
Countries |
| Widespread
Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis
Prevalence in South Africa |
|
| Women
and Children |
| Large
Numbers of Women and People of Color Can Be Successfully Enrolled in HIV
Studies in U.S. |
| Antiretroviral
Therapy for Mothers Improves Pregnancy Outcomes and Reduces Risk of
HIV Transmission via Breast-feeding |
HIV-HCV
and HIV-HBV Coinfection Articles |
| HIV-HCV
Coinfected Patients Treated with NRTI-Sparing Antiretroviral Regimens
Respond Better to Pegylated Interferon plus Ribavirin |
| Poor
Outcomes with Ribavirin Pre-treatment and Double-dose Pegylated Interferon in
HIV-HCV Coinfected Patients |
| Liver
Toxicity Related to Raltegravir (Isentress)
Is Uncommon among HIV Patients, including those with HIV-HCV Coinfection |
| Hepatitis
C Treatment and Normal Glucose Metabolism Promote Improved Fibrosis in HIV-HBV
Coinfected People |
| Antiretroviral
Regimens with Lamivudine (Epivir) Produce
Good CD4 Cell Recovery and HIV Suppression with Fewer Liver Flares in HIV-HBV
Coinfected Patients |
| Liver
Fibrosis May Regress in HIV-HCV Coinfected Patients
with Sustained Response to Pegylated Interferon plus
Ribavirin |
| |
Library
of Slides and Posters |
Therapies
for Treatment-Experienced Patients |
| Lopinavir/ritonavir
(LPV/r) tablets administered once- (DQ) or twice-daily (BID) with NRTIs
in antiretroviral-experienced HIV-1 infected subjects: Results of a 48-week randomized
trial (Study M06-802)
R Zajdenverg and others. IAS
2009. |
| Clinical
endpoints reduced through etravirine use in
treatment-experienced, HIV-1-infected patients: pooled 96-week results from the
Phase III DUET trials
J Eron and others. IAS 2009.
|
| Etravirine
demonstrates durable efficacy in treatment-experienced patients in the DUET trials:
pooled 96-week results
A Mills and others. IAS 2009.
|
| Long-term
safety profile of etravirine in treatment-experienced,
HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials
T
Campbell and others. IAS 2009. |
| Recovery
of Functional Immunity over 48 Weeks with Darunavir-based
Therapy in the GRACE Immunology Substudy
C Tsoukas
and others. IAS 2009. |
| GRACE
(Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based
Therapy in the Largest Trial in North America to Focus on Treatment-experienced
Women
K Squires and others. IAS 2009. |
| Integrase
Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical
Isolates from Patients Experiencing Virologic Failure while on Raltegravir
Therapy
M Underwood and others. IAS 2009. Copyright
GlaxoSmithKline. Used with permission, 2009. |
|
| First-Line
Therapy for Treatment-Naive Patients |
| Efficacy
and Safety of Atazanavir/RTV vs. Lopinavir/RTV
in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results
J Uy and others. IAS 2009. |
| Comparable
Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir
(LPV/r) Tablets With Emtricitabine (FTC) +
Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects:
96-Week Results of the Randomized Trial M05-730
J
Gonzalez and others. IAS 2009. |
| Prospective
randomised comparison of Nevirapine and Atazanavir/ritonavir
both combined with Tenofovir DF/Emtricitabine
in treatment-naïve HIV-1 infected patients: ARTEN Study week 48 results
V
Soriano and others. IAS 2009. |
| ARTEMIS:Week
96 safety and efficacy of darunavir/r by gender,
age and race
J Fourie and others. IAS 2009.
|
| Effects
of once-daily darunavir/ritonavir versus lopinavir/ritonavir
on lipid parameters and anthropometrics in treatment-naïve, HIV-1-infected ARTEMIS
patients at Week 96
E Baraldi and others. IAS 2009.
|
| Differences
in Virologic Response Among African-Americans and Females Regardless of Therapy
in the HEAT Study
K
Smith and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
|
| Similar
Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed
in Subjects Randomized to ABC/3TC or TDF/FTC
each with Lopinavir/Ritonavir (LPV/r) in the
HEAT Trial (EPZ104057)
L Yau and others. IAS 2009.
Copyright GlaxoSmithKline. Used with permission, 2009. |
| Similar
Efficacy and Tolerability of Atazanavir Compared
to Atazanavir/Ritonavir, each with ABC/3TC
after Initial Suppression with ABC/3TC + ATV/r
K
Squires and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission,
2009. |
|
| Experimental
HIV Therapies |
| Potent
Antiviral Activity of S/GSK1349572, A Next
Generation Integrase Inhibitor (INI), in INI-Naïve
HIV-1-Infected Patients: ING111521 Protocol
J Lalezari
and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009. |
| Pharmacokinetic
(PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572,
a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients
I
Song and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
|
| S/GSK1349572
is a Potent Next Generation HIV Integrase Inhibitor
A
Soto and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
|
| Pharmacokinetics
(PK) and Safety in Healthy Subjects of S/GSK1349572,
a Next Generation, Once-Daily HIV Integrase Inhibitor (INI)
S
Min and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
|
|
| Developing
Countries |
| The
Development of AntiRetroviral Therapy in Africa (DART)
trial
P Mugyenyi and others. IAS 2009.
|
|
| Special
Populations |
| 48
week lipid- and glucose-related safety profile of darunavir/ritonavir
in treatment-experienced, paediatric patients in DELPHI
T
Meyers and others. IAS 2009. |
| The
Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir
(ATV/r) Once Daily During Pregnancy: Results of Study AI424182
F
Conradie and others. IAS 2009. |
| Bioavailability
of Efavirenz Capsule Contents (Sprinkles)
Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults
S
Kaul and others. IAS 2009. |
|
| Treatment
Strategies |
| The
MONET trial: darunavir/ritonavir monotherapy
shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL
at baseline
J Arribas and others. IAS 2009. |
| The
FOTO Sudy- 48 week Results to assess durability of the strategy of
taking Efavirenz, Tenofovir and Emtricitabine
Five-days-On, Two-days-Off each week in virologically suppressed patients
C
Cohen and others. IAS 2009. |
|  |
